A new concept underlying stem cell lineage skewing that explains the detrimental effects of thiazolidinediones on bone

Stem Cells

Volumn 28, Issue 5, 2010, Pages 916-927

  Bruedigam, Claudia ^a   Eijken, Marco ^a   Koedam, Marijke ^a   Van De Peppel, Jeroen ^a   Drabek, Ksenija ^a   Chiba, Hideki ^b   Van Leeuwen, Johannes P T M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Bone formation; Mesenchymal stem cell; Osteoporosis; Oxidative stress; Peroxisome proliferator activated receptors; Thiazolidinediones

Indexed keywords

ISOPROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; ROSIGLITAZONE; REACTIVE OXYGEN METABOLITE; SHORT HAIRPIN RNA;

ADIPOCYTE; ADIPOGENESIS; APOPTOSIS; ARTICLE; BONE TISSUE; CELL DIFFERENTIATION; CELL LINEAGE; CONTROLLED STUDY; DRUG EFFECT; HEMATOPOIETIC STEM CELL; HUMAN; HUMAN CELL; HUMAN TISSUE; OSTEOBLAST; OXIDATIVE STRESS; PROTEIN EXPRESSION; BONE; BONE DEVELOPMENT; BONE MARROW CELL; CELL STIMULATION; GENE INACTIVATION; GENE OVEREXPRESSION; MESENCHYMAL STEM CELL; RNA INTERFERENCE;

ADIPOGENESIS; CELL DIFFERENTIATION; CELL LINE; CELL LINEAGE; CELLS, CULTURED; HUMANS; MESENCHYMAL STEM CELLS; OSTEOBLASTS; OSTEOGENESIS; OSTEOPOROSIS; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 77952344849     PISSN: 10665099     EISSN: None     Source Type: Journal    
DOI: 10.1002/stem.405     Document Type: Article

References (65)

1. Teng GG, Curtis JR, Saag KG. Mortality and osteoporotic fractures: is the link causal, and is it modifiable? Clin Exp Rheumatol 2008;26:S125-S137.
2. Genant HK, Cooper C, Poor G et al. Interim report and recommendations of the World Health Organization Task-Force for Osteoporosis. Osteoporos Int 1999;10:259-264. (Pubitemid 29476187)
3. Osteoporosis prevention, diagnosis, and therapy. Jama 2001;285:785-795.
4. Grey A, Bolland M, Gamble G et al. The peroxisome proliferator-activated receptor-gamma agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: A randomized, controlled trial. J Clin Endocrinol Metab 2007;92:1305-1310. (Pubitemid 46556402)
5. Lecka-Czernik B, Gubrij I, Moerman EJ et al. Inhibition of Osf2/Cbfa1 expression and terminal osteoblast differentiation by PPAR-gamma2. J Cell Biochem 1999;74:357-371. (Pubitemid 29344887)
6. Muruganandan S, Roman AA, Sinal CJ. Adipocyte differentiation of bone marrow-derived mesenchymal stem cells: Cross talk with the osteoblastogenic program. Cell Mol Life Sci 2009;66:236-253.
7. Moerman EJ, Teng K, Lipschitz DA et al. Aging activates adipogenic and suppresses osteogenic programs in mesenchymal marrow stroma/stem cells: The role of PPARgamma2 transcription factor and TGF-beta/BMP signaling pathways. Aging Cell 2004;3:379-389. (Pubitemid 40246708)
8. Zipori D. The stem state: Mesenchymal plasticity as a paradigm. Curr Stem Cell Res Ther 2006;1:95-102.
9. Lecka-Czernik B, Moerman EJ, Grant DF et al. Divergent effects of selective peroxisome proliferator-activated receptor-gamma 2 ligands on adipocyte versus osteoblast differentiation. Endocrinology 2002;143:2376-2384. (Pubitemid 34521584)
10. Lazarenko OP, Rzonca SO, Suva LJ et al. Netoglitazone is a PPARgamma ligand with selective effects on bone and fat. Bone 2006;38:74-84.
11. Ali AA, Weinstein RS, Stewart SA et al. Rosiglitazone causes bone loss in mice by suppressing osteoblast differentiation and bone formation. Endocrinology 2005;146:1226-1235.
12. Rzonca SO, Suva LJ, Gaddy D et al. Bone is a target for the antidiabetic compound rosiglitazone. Endocrinology 2004;145:401-406. (Pubitemid 38094536)
13. Akune T, Ohba S, Kamekura S et al. PPARgamma insufficiency enhances osteogenesis through osteoblast formation from bone marrow progenitors. J Clin Invest 2004;113:846-855. (Pubitemid 38544143)
14. Cock TA, Back J, Elefteriou F et al. Enhanced bone formation in lipodystrophic PPARgamma(hyp/hyp) mice relocates haematopoiesis to the spleen. EMBO Rep 2004;5:1007-1012. (Pubitemid 39534460)
15. Rosen ED, Spiegelman BM. PPARgamma: A nuclear regulator of metabolism, differentiation, and cell growth. J Biol Chem 2001;276:37731-37734. (Pubitemid 37384014)
16. Knouff C, Auwerx J. Peroxisome proliferator-activated receptor-gamma calls for activation in moderation: Lessons from genetics and pharmacology. Endocrine Rev 2004;25:899-918. (Pubitemid 39657772)
17. Lehrke M, Lazar MA. The many faces of PPARgamma. Cell 2005;123:993-999.
18. Forman BM, Chen J, Evans RM. Hypolipidemic drugs, polyunsaturated fatty acids, and eicosanoids are ligands for peroxisome proliferator-activated receptors alpha and delta. Proc Natl Acad Sci U S A 1997;94:4312-4317. (Pubitemid 27194238)
19. Kliewer SA, Sundseth SS, Jones SA et al. Fatty acids and eicosanoids regulate gene expression through direct interactions with peroxisome proliferator-activated receptors alpha and gamma. Proc Natl Acad Sci U S A 1997;94:4318-4323.
20. Krey G, Braissant O, L'Horset F et al. Fatty acids, eicosanoids, and hypolipidemic agents identified as ligands of peroxisome proliferator-activated receptors by coactivator-dependent receptor ligand assay. Mol Endocrinol 1997;11:779-791. (Pubitemid 27225305)
21. Picard F, Auwerx J. PPAR(gamma) and glucose homeostasis. Annu Rev Nutr 2002;22:167-197.
22. Werman A, Hollenberg A, Solanes G et al. Ligand-independent activation domain in the N terminus of peroxisome proliferator-activated receptor gamma (PPARgamma). Differential Activity Of PPARgamma1 And -2 Isoforms and Influence of Insulin. J Biol Chem 1997;272:20230-20235. (Pubitemid 27340134)
23. Tontonoz P, Hu E, Spiegelman BM. Stimulation of adipogenesis in fibroblasts by PPAR gamma 2, a lipid-activated transcription factor. Cell 1994;79:1147-1156.
24. Vidal-Puig AJ, Considine RV, Jimenez-Linan M et al. Peroxisome proliferator-activated receptor gene expression in human tissues. Effects Of Obesity, Weight Loss, And Regulation By Insulin and Glucocorticoids. J Clin Invest 1997;99:2416-2422. (Pubitemid 27227719)
25. Bruedigam C, Koedam M, Chiba H et al. Evidence for multiple peroxisome proliferator-activated receptor gamma transcripts in bone: fine-tuning by hormonal regulation and mRNA stability. FEBS Lett 2008;582:1618-1624.
26. Chiba H, Sawada N, Ono T et al. Establishment and characterization of a simian virus 40-immortalized osteoblastic cell line from normal human bone. Jpn J Cancer Res 1993;84:290-297. (Pubitemid 23104313)
27. Eijken M, Koedam M, van Driel M et al. The essential role of glucocorticoids for proper human osteoblast differentiation and matrix mineralization. Mol Cell Endocrinol 2006;248:87-93.
28. Vidal-Puig A, Jimenez-Linan M, Lowell BB et al. Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest 1996;97:2553-2561. (Pubitemid 26187343)
29. Saladin R, Fajas L, Dana S et al. Differential regulation of peroxisome proliferator activated receptor gamma1 (PPARgamma1) and PPARgamma2 messenger RNA expression in the early stages of adipogenesis. Cell Growth Differ 1999;10:43-48. (Pubitemid 29086918)
30. Patel DD, Knight BL, Wiggins D et al. Disturbances in the normal regulation of SREBP-sensitive genes in PPAR alpha-deficient mice. J Lipid Res 2001;42:328-337. (Pubitemid 32270055)
31. Gillies PS, Dunn CJ. Pioglitazone Drugs. 2000;60:333-343, discussion 344-1335
32. Plosker GL, Faulds D. Troglitazone: A review of its use in the management of type 2 diabetes mellitus. Drugs 1999;57:409-438. (Pubitemid 29137484)
33. Kiyota Y, Kondo T, Maeshiba Y et al. Studies on the metabolism of the new antidiabetic agent pioglitazone. Identification of metabolites in rats and dogs. Arzneimittelforschung 1997;47:22-28. (Pubitemid 27083325)
34. Yee LD, Williams N, Wen P et al. Pilot study of rosiglitazone therapy in women with breast cancer: effects of short-term therapy on tumor tissue and serum markers. Clin Cancer Res 2007;13:246-252. (Pubitemid 46121876)
35. Warren LA, Rossi DJ. Stem cells and aging in the hematopoietic system. Mech Ageing Dev 2009;130:46-53.
36. Yu R, Mandlekar S, Lei W et al. p38 mitogen-activated protein kinase negatively regulates the induction of phase II drug-metabolizing enzymes that detoxify carcinogens. J Biol Chem 2000;275:2322-2327. (Pubitemid 30081988)
37. Kawai M, Devlin MJ, Rosen CJ. Fat targets for skeletal health. Nat Rev Rheumatol 2009;5:365-372.
38. Khan E, Abu-Amer Y. Activation of peroxisome proliferator-activated receptor-gamma inhibits differentiation of preosteoblasts. J Lab Clin Med 2003;142:29-34. (Pubitemid 36930414)
39. Jeon MJ, Kim JA, Kwon SH et al. Activation of peroxisome proliferator-activated receptor-gamma inhibits the Runx2-mediated transcription of osteocalcin in osteoblasts. J Biol Chem 2003;278:23270-23277.
40. Watanabe S, Takeuchi Y, Fukumoto S et al. Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab 2003;21:166-171. (Pubitemid 41184298)
41. Cornish J, Callon KE, King AR et al. Systemic administration of amylin increases bone mass, linear growth, and adiposity in adult male mice. Am J Physiol 1998;275:E694-699. (Pubitemid 28500707)
42. Cornish J, Callon KE, Reid IR. Insulin increases histomorphometric indices of bone formation in vivo. Calcif Tissue Int 1996;59:492-495. (Pubitemid 26397171)
43. Lecka-Czernik B, Ackert-Bicknell C, Adamo ML et al. Activation of peroxisome proliferator-activated receptor gamma (PPARgamma) by rosiglitazone suppresses components of the insulin-like growth factor regulatory system in vitro and in vivo. Endocrinology 2007;148:903-911. (Pubitemid 46143190)
44. Rubin GL, Zhao Y, Kalus AM et al. Peroxisome proliferator-activated receptor gamma ligands inhibit estrogen biosynthesis in human breast adipose tissue: Possible implications for breast cancer therapy. Cancer Res 2000;60:1604-1608. (Pubitemid 30183431)
45. Wan Y, Chong LW, Evans RM. PPAR-gamma regulates osteoclasto-genesis in mice. Nat Med 2007;13:1496-1503.
46. Kobayashi H, Gao Y, Ueta C et al. Multilineage differentiation of Cbfa1-deficient calvarial cells in vitro. Biochem Biophys Res Commun 2000;273:630-636. (Pubitemid 30599036)
47. Liu W, Toyosawa S, Furuichi T et al. Overexpression of Cbfa1 in osteoblasts inhibits osteoblast maturation and causes osteopenia with multiple fractures. J Cell Biol 2001;155:157-166. (Pubitemid 34286216)
48. Kletzien RF, Clarke SD, Ulrich RG. Enhancement of adipocyte differentiation by an insulin-sensitizing agent. Mol Pharmacol 1992;41:393-398.
49. Gimble JM, Robinson CE, Wu X et al. Peroxisome proliferator-activated receptor-gamma activation by thiazolidinediones induces adipogenesis in bone marrow stromal cells. Mol Pharmacol 1996;50:1087-1094. (Pubitemid 26384846)
50. Komarova SV, Ataullakhanov FI, Globus RK. Bioenergetics and mitochondrial transmembrane potential during differentiation of cultured osteoblasts. Am J Physiol 2000;279:C1220-1229.
51. Chen CT, Shih YR, Kuo TK et al. Coordinated changes of mitochondrial biogenesis and antioxidant enzymes during osteogenic differentiation of human mesenchymal stem cells. Stem Cells 2008;26:960-968.
52. Wenz T, Diaz F, Spiegelman BM et al. Activation of the PPAR/PGC-1alpha pathway prevents a bioenergetic deficit and effectively improves a mitochondrial myopathy phenotype. Cell Metab 2008;8:249-256.
53. Wang YL, Frauwirth KA, Rangwala SM et al. Thiazolidinedione activation of peroxisome proliferator-activated receptor gamma can enhance mitochondrial potential and promote cell survival. J Biol Chem 2002;277:31781-31788.
54. Bova MP, Tam D, McMahon G et al. Troglitazone induces a rapid drop of mitochondrial membrane potential in liver HepG2 cells. Toxicol Lett 2005;155:41-50. (Pubitemid 39600735)
55. Dello Russo C, Gavrilyuk V, Weinberg G et al. Peroxisome proliferator-activated receptor gamma thiazolidinedione agonists increase glucose metabolism in astrocytes. J Biol Chem 2003;278:5828-5836. (Pubitemid 36800829)
56. Guarente L. Sirtuins in aging and disease. Cold Spring Harbor symposia on quantitative biology. 2007;72:483-488.
57. Eckert A, Keil U, Marques CA et al. Mitochondrial dysfunction, apoptotic cell death, and Alzheimer's disease. Biochem Pharmacol 2003;66:1627-1634. (Pubitemid 38373355)
58. Elbaz A, Wu X, Rivas D et al. Inhibition of Fatty Acid Biosynthesis Prevents Adipocyte Lipotoxicity on Human Osteoblasts In Vitro. J Cell Mol Med 2009.
59. Jung JY, Yoo CI, Kim HT et al. Role of mitogen-activated protein kinase (MAPK) in troglitazone-induced osteoblastic cell death. Toxicology 2007;234:73-82. (Pubitemid 46517825)
60. Kim SH, Yoo CI, Kim HT et al. Activation of peroxisome proliferator-activated receptor-gamma (PPARgamma) induces cell death through MAPK-dependent mechanism in osteoblastic cells. Toxicol Appl Pharmacol 2006;215:198-207.
61. Sorocéanu MA, Miao D, Bai XY et al. Rosiglitazone impacts negatively on bone by promoting osteoblast/osteocyte apoptosis. J Endocrinol 2004;183:203-216. (Pubitemid 40124657)
62. Ackert-Bicknell CL, Shockley KR, Horton LG et al. Strain-specific effects of rosiglitazone on bone mass, body composition, and serum insulin-like growth factor-I. Endocrinology 2009;150:1330-1340.
63. Almeida M, Han L, Martin-Millan M et al. Skeletal involution by age-associated oxidative stress and its acceleration by loss of sex steroids. J Biol Chem 2007;282:27285-27297. (Pubitemid 47501960)
64. Almeida M, Ambrogini E, Han L et al. Increased lipid oxidation causes oxidative stress, increased peroxisome proliferator-activated receptor-gamma expression, and diminished pro-osteogenic Wnt signaling in the skeleton. J Biol Chem 2009;284:27438-27448.
65. Weinstein RS, Jilka RL, Parfitt AM et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. J Clin Invest 1998;102:274-282.